Oncology Business Management

The FDA has approved abiraterone acetate in combination with prednisone prior to chemotherapy for the treatment of men with metastatic castration-resistant prostate cancer.

Oncologists should be aware that the need to refer patients between ACO members can raise legal issues for practices and should consider two key laws before participating.

The FDA approved cabozantinib, a multi-targeted tyrosine kinase inhibitor, for the treatment of metastatic medullary thyroid cancer.

In-house dispensing of oral agents in the community oncology setting may provide a safer and more reliable and convenient way for patients to receive their medications.

Pertuzumab, a new HER2-positive breast cancer drug, is being launched at a 31% premium to the price of trastuzumab.

Medical homes are physician-led healthcare teams that coordinate care for patients and typically rely on electronic methods for record-keeping, care coordination, and data collection.

Amatuximab has received orphan drug status from the FDA to treat patients with malignant pleural mesothelioma, the most common form of mesothelioma.

William K. Oh, MD, from the Tisch Cancer Institute, discusses strategies for sequencing the new therapies that have been approved for treating castration-resistant prostate cancer.

The last year of life is associated with high health expenditures in the United States, and the costs are increasingly focused on patients' last few months.

Stakeholders weigh in on evidence-based pathway approach designed to decrease practice variation, improve outcomes, and reduce cost.

Community oncologists must weigh multiple factors when deciding to consolidate or remain independent.

Researchers have identified a potential predictive marker for survival in cases of metastatic colorectal cancer treated with bevacizumab.

Integrative model unites physicians, hospitals, and payers to deliver evidence-based care and control cancer costs.

The promise of a solution somewhere on the horizon for America's drug shortages isn't enough for the registered nurse who navigates shortages every day.

The FDA has approved nab-paclitaxel plus carboplatin for patients with untreated locally advanced or metastatic NSCLC who are not candidates for surgery or radiation.

Daniel P. Petrylak, MD, from the Smilow Cancer Center, discusses the recent approval and future role of enzalutamide for patients with prostate cancer.

Driven by changes in reimbursement and standards of care, independent community oncology practices continue to dwindle.

As with most industries where outcome metrics are crucial for continued success, the government is wanting physicians to deliver care that is outcome- and evidence-based.

This fellow shares the insights he’s gained from his wife, a pediatric oncology nurse, and how they help in the care he provides.

Pretreatment serum lactate dehydrogenase is a prognostic factor in poor-risk patients with renal cell carcinoma and also a predictive factor for a survival benefit from treatment with temsirolimus.